Metropolitan Life Insurance Company (MetLife)’s Unity Biotechnology UBX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,038	Closed	-$90.1K	–	2592
2020 Q2	$90.1K	Buy	1,038 +810	+355%	+$60.1K	﹤0.01%	2316
2020 Q1	$13.2K	Buy	+228	New	+$14.4K	﹤0.01%	2472
2019 Q3	–	Sell	-232	Closed	-$22K	–	2628
2019 Q2	$22K	Buy	+232	New	+$19.7K	﹤0.01%	2593
2019 Q1	–	Sell	-883	Closed	-$144K	–	2571
2018 Q4	$144K	Buy	+883	New	+$117K	﹤0.01%	2036

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s UBX Position: Q3 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 1,038 shares — an estimated $90.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in UBX in Q4 2018 and held it in 4 quarters. The position peaked at $144K in Q4 2018. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

Metropolitan Life Insurance Company (MetLife) reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,038 Unity Biotechnology shares in Q3 2020, an estimated $90.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Unity Biotechnology in Q4 2018 and held it in 4 quarters.
Metropolitan Life Insurance Company (MetLife)'s Unity Biotechnology position peaked at $144K in Q4 2018.
79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2020, filed 13 Nov 2020.